Vibegron

Vibegron
Clinical data
Trade names	Gemtesa
Other names	KRP-114V, MK-4618, RVT-901, URO-901
AHFS/Drugs.com	Monograph
License data	US DailyMed: Vibegron;
Routes of; administration	By mouth
Drug class	Beta3 adrenergic receptor agonist
ATC code	G04BD15 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	49.6 to 51.3% is bound to plasma proteins
Metabolism	Predominantly oxidation and glucuronidation
Elimination half-life	60 to 70 hours
Excretion	59% feces (54% of this is in the unchanged parent drug form), 20% urine (19% of this is in the unchanged parent drug form)
Identifiers
	IUPAC name (6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide;
CAS Number	1190389-15-1;
PubChem CID	44472635;
DrugBank	DB14895;
ChemSpider	28528047;
UNII	M5TSE03W5U;
KEGG	D10433;
ChEBI	CHEBI:142418;
ChEMBL	ChEMBL2107826;
CompTox Dashboard (EPA)	DTXSID40152299 ;
ECHA InfoCard	100.210.547
Chemical and physical data
Formula	C26H28N4O3
Molar mass	444.535 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21;
	InChI InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1; Key:DJXRIQMCROIRCZ-XOEOCAAJSA-N;

Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. Vibegron is a selective beta-3 adrenergic receptor agonist.

The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection.

Vibegron was first discovered by scientists at Merck & Co. Inc. and was later developed in Japan by Kyorin Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, and Urovant Sciences. It was approved for medical use in Japan in September 2018, in the United States in December 2020, and in the European Union in June 2024.